HYSERPIN
Clinical safety rating: caution
Comprehensive clinical and safety monograph for HYSERPIN (HYSERPIN).
Hyserpin is a combination of reserpine and hydralazine. Reserpine depletes catecholamines and serotonin from nerve endings by inhibiting vesicular monoamine transporter (VMAT). Hydralazine is a direct arteriolar vasodilator that reduces peripheral resistance via relaxation of vascular smooth muscle, possibly through nitric oxide-mediated pathways.
| Metabolism | Reserpine: extensively metabolized in the liver via cytochrome P450 enzymes; hydralazine: primarily metabolized by N-acetylation (polymorphic) and oxidation. |
| Excretion | Renal: 50-60% unchanged; biliary/fecal: 30-40% as metabolites |
| Half-life | Terminal elimination half-life: 12-16 hours; clinical context: supports twice-daily dosing for hypertension |
| Protein binding | 85-93%; primarily bound to albumin and alpha-1-acid glycoprotein |
| Volume of Distribution | 2-4 L/kg; indicates extensive tissue distribution, higher in hypertensive patients |
| Bioavailability | Oral: 50-60%; intramuscular: 70-80% |
| Onset of Action | Oral: 30-60 minutes; Intravenous: 5-10 minutes; Intramuscular: 15-30 minutes |
| Duration of Action | Oral: 6-12 hours; intravenous/intramuscular: 4-8 hours; prolonged with renal impairment |
Oral: 0.1-0.25 mg twice daily. Maximum dose: 0.5 mg daily.
| Dosage form | TABLET |
| Renal impairment | Not dialyzable. No specific GFR-based adjustments; use with caution in severe impairment. |
| Liver impairment | Child-Pugh Class B or C: reduce dose by 50% or increase dosing interval (e.g., once daily). |
| Pediatric use | Not recommended due to lack of safety and efficacy data. Avoid in children. |
| Geriatric use | Initiate at 0.05 mg once daily; titrate slowly to minimize hypotension and CNS effects. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for HYSERPIN (HYSERPIN).
| Breastfeeding | Reserpine is excreted into breast milk. M/P ratio not well characterized. Potential for adverse effects in nursing infants (nasal congestion, bradycardia). Avoid breastfeeding while on Hyserpin due to infant risks. |
| Teratogenic Risk | Hypertension itself poses risks to the fetus (e.g., placental insufficiency, growth restriction). For antihypertensives in general: first trimester: no major teratogenicity known for most agents; second/third trimester: risk of fetal hypotension, hypoxia, and growth restriction. Specific to Hyserpin (reserpine): animal studies show possible teratogenic effects; human data limited. Avoid in pregnancy especially third trimester due to risk of neonatal bradycardia, hypothermia, and nasal congestion. |
■ FDA Black Box Warning
None
| Serious Effects |
["Known hypersensitivity to any component","History of mental depression (reserpine)","Active peptic ulcer (reserpine)","Ulcerative colitis (reserpine)","Electroconvulsive therapy (reserpine)"]
| Precautions | ["Risk of mental depression (reserpine)","Orthostatic hypotension","Lupus-like syndrome (hydralazine, especially in slow acetylators)","Peripheral neuropathy (hydralazine, due to pyridoxine deficiency)"] |
Loading safety data…
| Fetal Monitoring | Monitor maternal blood pressure, heart rate, and signs of depression (potential adverse effect). Fetal monitoring: ultrasound for growth, non-stress test or biophysical profile in third trimester if chronic hypertension. |
| Fertility Effects | Reserpine may impair fertility in males due to decreased libido and possible impairment of sexual function. No specific human studies on female fertility; theoretical effect on reproductive hormones (catecholamine depletion). |